advanced search

INJECTION

INDUSTRIALISATION
LYOPHILISATION VIALS: QUICK AND EFFECTIVE SOLUTIONS TO REDUCE FOGGING
Diane McCormick and Clément Condouret discuss lyophilisation fogging, explaining its negative downstream effects and presenting NIPRO’s thermal treatment, VIALEX™, to minimise this issue.
INDUSTRIALISATION
DESIGNING FOR SCALE: RELIABLE MANUFACTURING OF PEN INJECTOR PLATFORMS
Henrik Leisner discusses the reliable scaling of pen injector programmes, considering how high-quality, high-volume manufacture depends on experience and collaboration.
INNOVATION AND AUTOMATION REUNITED – ENABLING SCALABLE FINAL ASSEMBLY FOR CARTRIDGE-BASED AUTOINJECTORS
INDUSTRIALISATION
Christy Chen
SHL Advantec
INNOVATION AND AUTOMATION REUNITED – ENABLING SCALABLE FINAL ASSEMBLY FOR CARTRIDGE-BASED AUTOINJECTORS
Using SHL Medical's Reunite™ dual-chamber autoinjector and SHL Advantec's AOU™ assembly machine platform as a case study, Christy Chen and Alberto Flores explore the critical synergy between flexible automation architecture and expert final assembly services.
PHARMASHELL – AN ALD NANOCOATING TECHNOLOGY FOR ONCE-MONTHLY INJECTABLES
FORMULATION
Dr Anders Johansson
Nanexa
PHARMASHELL – AN ALD NANOCOATING TECHNOLOGY FOR ONCE-MONTHLY INJECTABLES
Dr Anders Johansson, Dr Polla Rouf and Dr Oliver Hedge introduce Nanexa’s PharmaShell® technology and discuss how, in combination with nanotechnology, it can achieve previously unattainable dosing intervals with
standard formulations.
INDUSTRIALISING DRUG DELIVERY DEVICES: INSIGHTS FROM 40 YEARS OF GETTING TO MARKET
EXPERT VIEW
Chris Hurlstone
INDUSTRIALISING DRUG DELIVERY DEVICES: INSIGHTS FROM 40 YEARS OF GETTING TO MARKET
Chris Hurlstone looks at the process of developing drug delivery systems through the industrialisation phase and explores ways to address the challenges that arise along the way. Drawing on Team’s 40-year track record of supporting drug delivery device innovation, the insights are intended for teams involved in developing drug delivery systems, particularly those responsible for design, engineering, industrialisation and manufacturing transfer.
INDUSTRIALISING DRUG DELIVERY IN AN UNCERTAIN WORLD
INDUSTRIALISATION
Andy Wertheim
Quvara Medical
INDUSTRIALISING DRUG DELIVERY IN AN UNCERTAIN WORLD
Andy Wertheim considers how the priorities of drug delivery device industrialisation have shifted in response to the major supply chain shocks of recent years, with companies shifting their focus from purely optimising for low cost and putting much greater emphasis on security and continuity, and what these changing priorities imply for the industry as a whole.
DE-RISKING POST-MARKET CHANGE THROUGH PILOT PRODUCTION
EXPERT VIEW
Jon Powell
DE-RISKING POST-MARKET CHANGE THROUGH PILOT PRODUCTION
Jon Powell explores how pilot production, delivered through integrated design, development and manufacturing capabilities, can be used to de-risk change in commercial-scale drug delivery devices, highlighting how such approaches can improve confidence in decision-making while reducing overall time and cost.
HOW MODERN PROTOTYPING ACCELERATES DRUG DELIVERY DEVICE DEVELOPMENT
INDUSTRIALISATION
Erwin van Huijksloot
IGS GeboJagema
HOW MODERN PROTOTYPING ACCELERATES DRUG DELIVERY DEVICE DEVELOPMENT
Erwin van Huijksloot and Joe Melton discuss the importance of early prototyping, ensuring a strong understanding of production efficiency and possible variability is grasped before large-scale manufacture begins.
Technology Showcase: DIGITAL TWIN TECHNOLOGY FOR AUTOINJECTORS
SHOWCASE
Covestro LLC
Technology Showcase: DIGITAL TWIN TECHNOLOGY FOR AUTOINJECTORS
Covestro outlines how digital twin methodologies, physics-based virtual models spanning structural testing, drop-test simulation and injection-moulding analysis, are helping engineers develop polycarbonate autoinjector components, reducing physical prototyping, tooling iterations and time to market while maintaining safety and reliability.
Testing Prefilled Syringes to ISO 11040
INJECTION
Landon Goldfarb
Instron
Testing Prefilled Syringes to ISO 11040
Instron's Landon Goldfarb talks through ISO 11040, a testing standard that addresses the design and functional properties of prefilled syringes.
Interview: Celebrating 10 Years of Molly Enabling Patients’ Independence
INTERVIEW
Nicholas Heaton
SHL Medical
Interview: Celebrating 10 Years of Molly Enabling Patients’ Independence
Nicholas Heaton looks back on the decade since Molly – SHL Medical’s signature two-step autoinjector platform – was launched onto the market, reviewing what made the device platform a success, where Molly is positioned in the market today and how it will continue to evolve to meet the demands of the future.
FROM SMALL TO LARGE MOLECULES: ADVANCING PRECISION PUMP TECHNOLOGY FOR BIOLOGIC DRUG DELIVERY
WEARABLES
Dr Ines Rüstenberg
Gerresheimer
FROM SMALL TO LARGE MOLECULES: ADVANCING PRECISION PUMP TECHNOLOGY FOR BIOLOGIC DRUG DELIVERY
Dr Ines Rüstenberg, Roger Müller and Dr Yannick Schmid, discuss solutions for large-molecule drug delivery, highlighting the applicability of two infusors, Gx InPuls and Gx InPuls Flex, which employ micropump technology to overcome challenges with large-molecule delivery.
Interview: GLP-1 Demand and the New Reality of Device Manufacturing Capacity
INTERVIEW
Andy Wertheim
Quvara Medical
Interview: GLP-1 Demand and the New Reality of Device Manufacturing Capacity
Andy Wertheim discusses the growing shortage of available manufacturing capacity driven by the boom in GLP-1 therapies, why this means mid-volume development programmes across a range of sectors are struggling to move from development to industrialisation, and how Quvara Medical is ideally positioned to provide the capacity that these programmes lack.
CLOSING THE SAFETY GAP: WHY PHARMA-DEDICATED LABELS MATTER
INDUSTRIALISATION
Paavo Sillanpää
UPM Adhesive Materials
CLOSING THE SAFETY GAP: WHY PHARMA-DEDICATED LABELS MATTER
Paavo Sillanpää discusses why pharma-dedicated labels matter for more challenging labelling applications as well as how to avoid potential label failure and brand risk.
ADVANCING AUTOINJECTOR PLATFORMS FOR EVOLVING DRUG AND PATIENT NEEDS
INJECTION
Martin Høier Thomsen
MGS Mfg Group
ADVANCING AUTOINJECTOR PLATFORMS FOR EVOLVING DRUG AND PATIENT NEEDS
Martin Høier Thomsen introduces MGS’s A.i.r. Platform™ within the broader context of the evolution of autoinjector platforms towards more adaptable, customisable solutions. He considers how next-generation autoinjector platforms can address increasingly complex and changing demands, while helping to mitigate risk and prioritise usability.
IMPORTANCE OF BEING PATIENT-CENTRIC IN CARDIOVASCULAR-KIDNEY-METABOLIC CARE
INJECTION
Cecile Gross
Nemera
IMPORTANCE OF BEING PATIENT-CENTRIC IN CARDIOVASCULAR-KIDNEY-METABOLIC CARE
Cécile Gross and Mark Tunkel discuss Nemera's substantial portfolio of user-friendly, effective injectable devices available to meet the needs of patients with diverse chronic conditions.
DEORA™: FILLING THE GAP FOR MULTI-USE, FIXED-DOSE INJECTION SOLUTIONS
INJECTION
Manuela Giacon
Stevanato Group
DEORA™: FILLING THE GAP FOR MULTI-USE, FIXED-DOSE INJECTION SOLUTIONS
Manuela Giacon explores the evolution of handheld drug delivery devices, leading up to today’s challenges, and presents the company’s latest addition to its drug delivery portfolio.
LVSC DELIVERY: HOW VOLUME AND CONCENTRATION REQUIREMENTS ARE RESHAPING DEVICE SELECTION
WEARABLES
Tony Bedford
Phillips Medisize
LVSC DELIVERY: HOW VOLUME AND CONCENTRATION REQUIREMENTS ARE RESHAPING DEVICE SELECTION
Tony Bedford considers how the rise in biologic formulations together with a strong shift towards subcutaneous administration is shaping the drug delivery industry, particularly in relation to large-volume subcutaneous delivery.
AUTOINJECTOR TECHNOLOGY FOR AUTOMATIC MICROPARTICLE SUSPENSION AND INJECTION
INJECTION
Girum Yemane-Tekeste
Kindeva
AUTOINJECTOR TECHNOLOGY FOR AUTOMATIC MICROPARTICLE SUSPENSION AND INJECTION
Girum Yemane-Tekeste and Stephen Leslie share how Kindeva is building on its experience and history of innovation to develop an enabling technology for injectable microparticles and then evaluating it through proof-of-principle testing.
EARLY DECISIONS, FASTER LAUNCH: OPTIMISING COMBINATION PRODUCT COMMERCIALISATION
INJECTION
Bill Welch
PCI Pharma Services
EARLY DECISIONS, FASTER LAUNCH: OPTIMISING COMBINATION PRODUCT COMMERCIALISATION
Bill Welch explores how early development selections, structured timelines and adoption of a “path of least resistance” can reduce technical, regulatory and commercial risk, thereby optimising product commercialisation.
INJECTABLE COLLAGEN – PRESENT AND FUTURE POTENTIAL
INJECTION
Martin Junginger
GELITA
INJECTABLE COLLAGEN – PRESENT AND FUTURE POTENTIAL
Martin Junginger discusses the advantages and challenges of delivering collagen via injection, considering the role that collagen plays in the current healthcare landscape, including GELITA's VACCIPRO® and MEDELLAPRO® collagen grades, and sharing insights on how that role may grow and adapt going forwards.
EXCIPIENT LANDSCAPES: HIGH-THROUGHPUT SCREENING TO SOLVE VISCOSITY BOTTLENECKS FOR BIOLOGIC THERAPEUTICS
EARLY INSIGHT
Dr Scott Compel
AEMS Corp
EXCIPIENT LANDSCAPES: HIGH-THROUGHPUT SCREENING TO SOLVE VISCOSITY BOTTLENECKS FOR BIOLOGIC THERAPEUTICS
Dr Scott Compel and Dr Alex Hendricks discuss AEMS Corp's automated, microscale screening platform that enables viscosity reduction, using innovative approaches to test excipient combinations effectively.
SCALING RADIOLIGAND THERAPY: WHY PACKAGING AND DELIVERY SYSTEMS MUST EVOLVE
EARLY INSIGHT
Dr Eva Littringer
Oncofuse
SCALING RADIOLIGAND THERAPY: WHY PACKAGING AND DELIVERY SYSTEMS MUST EVOLVE
Dr Eva Littringer and Dr Roland Starlinger discuss the exciting new frontier of radioligand therapy and the imminent bottleneck presented by current delivery methods running into strict limits on handling radioactive materials. They go on to introduce the Oncofuse prefilled-syringe-based system as a novel approach to containment and handling of these therapies, enabling radioligand therapy to expand beyond niche specialist clinics and hospitals.
CONQUERING COMPLEXITY WITH LIFECORE INJECTABLES
SHOWCASE
Lifecore Injectables
CONQUERING COMPLEXITY WITH LIFECORE INJECTABLES
Lifecore Injectable, a US-based injectables CDMO, has built a reputation for embracing complex process development and manufacturing challenges that others avoid. This mindset is rooted in the company’s legacy as a manufacturer of sodium hyaluronate, a highly viscous material known for being difficult to filter and fill.
EXPANDING SUBCUTANEOUS DESIGN BRICK BY BRICK: THE BD NEOPAK™ GLASS PREFILLABLE SYRINGE PLATFORM
PREFILLED SYRINGES
Hervé Soukiassian
BD (Becton Dickinson & Company)
EXPANDING SUBCUTANEOUS DESIGN BRICK BY BRICK: THE BD NEOPAK™ GLASS PREFILLABLE SYRINGE PLATFORM
Hervé Soukiassian and Sophie Lelias discuss the established injection platforms built to achieve reliable and efficient subcutaneous delivery, going further to examine new injectable devices in development that are designed for an optimised patient experience as well as higher-volume, higher-viscosity delivery.
BEYOND THE BARREL: PREFILLED SYRINGES THAT FOLD IN HALF
EARLY INSIGHT
Ian Speers
Pacto Medical
BEYOND THE BARREL: PREFILLED SYRINGES THAT FOLD IN HALF
Ian Speers, Robert Halvorsen and Ryan Stinebaugh discuss the unmet needs in prefilled deployability that led to the development of Slimshot™, a detached plunger rod that nests alongside the syringe, and Slimshot™ Doser, a companion concept designed to reduce the mental load of variable dosing in high-pressure delivery situations, and how these concepts can contribute to improved workflows and logistics throughout the healthcare sector.
Top